BRPI0911871A8 - uso de partículas veículo sólidas para melhorar a processabilidade de um agente farmacêutico - Google Patents

uso de partículas veículo sólidas para melhorar a processabilidade de um agente farmacêutico Download PDF

Info

Publication number: BRPI0911871A8
Authority: BR; Brazil
Prior art keywords: pharmaceutical agent; carrier particles; solid carrier; improve processability; processability
Prior art date: 2008-05-02

Application number

BRPI0911871A

Other languages

English (en)

Inventor

A Mathias Anita

P Kearney Brian

M Koziara Joanna

M Menning Mark

Oliyai Reza

Yu Richard

G Strickley Robert

Original Assignee

Gilead Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-05-02

Filing date

2009-05-01

Publication date

2018-03-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40809930&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0911871(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-05-01 Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc

2015-11-17 Publication of BRPI0911871A2 publication Critical patent/BRPI0911871A2/pt

2018-03-06 Publication of BRPI0911871A8 publication Critical patent/BRPI0911871A8/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Inorganic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
AIDS & HIV (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines Containing Plant Substances (AREA)

BRPI0911871A 2008-05-02 2009-05-01 uso de partículas veículo sólidas para melhorar a processabilidade de um agente farmacêutico BRPI0911871A8 (pt)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US4993508P	2008-05-02	2008-05-02
US15065209P	2009-02-06	2009-02-06
US15065509P	2009-02-06	2009-02-06
PCT/US2009/042607 WO2009135179A2 (en)	2008-05-02	2009-05-01	The use of solid carrier particles to improve the processability of a pharmaceutical agent

Publications (2)

Publication Number	Publication Date
BRPI0911871A2 BRPI0911871A2 (pt)	2015-11-17
BRPI0911871A8 true BRPI0911871A8 (pt)	2018-03-06

Family

ID=40809930

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0911871A BRPI0911871A8 (pt)	2008-05-02	2009-05-01	uso de partículas veículo sólidas para melhorar a processabilidade de um agente farmacêutico

Country Status (27)

Country	Link
US (1)	US10039718B2 (pt)
EP (2)	EP3006032A1 (pt)
JP (2)	JP5722213B2 (pt)
KR (2)	KR101784647B1 (pt)
CN (3)	CN104940937A (pt)
AP (1)	AP3089A (pt)
AU (3)	AU2009242451C1 (pt)
BR (1)	BRPI0911871A8 (pt)
CA (1)	CA2720856C (pt)
CO (1)	CO6321225A2 (pt)
CY (1)	CY1117067T1 (pt)
DK (1)	DK2296633T3 (pt)
EA (2)	EA201591353A1 (pt)
EC (1)	ECSP10010636A (pt)
ES (1)	ES2553897T3 (pt)
HK (2)	HK1153670A1 (pt)
HR (1)	HRP20151357T1 (pt)
HU (1)	HUE026380T2 (pt)
IL (2)	IL208614A (pt)
MX (2)	MX2010011963A (pt)
NZ (1)	NZ588978A (pt)
PL (1)	PL2296633T3 (pt)
PT (1)	PT2296633E (pt)
SG (2)	SG190618A1 (pt)
SI (1)	SI2296633T1 (pt)
WO (1)	WO2009135179A2 (pt)
ZA (1)	ZA201008007B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI2049506T2 (sl)	2006-07-07	2024-07-31	Gilead Sciences, Inc.	Modulatorji farmakokinetičnih lastnosti terapevtikov
PL2487161T5 (pl) *	2007-02-23	2024-09-09	Gilead Sciences, Inc.	<div>Modulatory właściwości farmakokinetycznych środków terapeutycznych</div><div> </div>
CN101743004A (zh) *	2007-06-29	2010-06-16	吉里德科学公司	治疗用组合物及其用途
BRPI0813000A2 (pt) *	2007-06-29	2014-12-23	Gilead Sciences Inc	Composições terapêuticas e uso das mesmas
BRPI0911871A8 (pt)	2008-05-02	2018-03-06	Gilead Sciences Inc	uso de partículas veículo sólidas para melhorar a processabilidade de um agente farmacêutico
UA108738C2 (uk)	2009-04-03	2015-06-10		Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки
CN103491948B (zh)	2010-11-19	2016-11-02	吉利德科学公司	包含利匹韦林HCl和富马酸替诺福韦酯的治疗组合物
ES2543923T3 (es) *	2011-05-02	2015-08-25	Gilead Sciences, Inc.	Sales sólidas amorfas de Cobicistat (GS-9350)
SI2729130T1 (en)	2011-07-07	2018-03-30	Janssen Sciences Ireland Uc	Combined formulations of darunavir
FI2744810T4 (fi)	2011-08-16	2023-11-22	Gilead Sciences Inc	Tenofoviirialafenamidihemifumaraatti
JP2015503624A (ja)	2012-01-12	2015-02-02	ギリアードサイエンシーズ，インコーポレイテッド	医薬組成物およびその調製方法
WO2013116715A1 (en)	2012-02-03	2013-08-08	Gilead Sciences, Inc.	Methods and intermediates for preparing pharmaceutical agents
EP2819644A1 (en)	2012-03-01	2015-01-07	Gilead Sciences, Inc.	Spray dried formulations
AU2013336491B2 (en) *	2012-10-23	2018-08-02	Cipla Limited	Pharmaceutical antiretroviral composition
EP2938603A1 (en) *	2012-12-26	2015-11-04	Assia Chemical Industries Ltd.	Cobicostat dichlohydrate salt
DE102013205347A1 (de)	2013-03-26	2014-10-02	Hilti Aktiengesellschaft	Additiv-Zusammensetzung für Amin-Härter, deren Verwendung sowie diese enthaltende Amin-Härterzusammensetzung
CN103230403A (zh) *	2013-04-23	2013-08-07	苏州谷力生物科技有限公司	一种抗艾滋病毒的组合型药物片剂
US20170035911A1 (en) *	2013-11-29	2017-02-09	Mylan Laboratories Ltd.	Amorphous Cobicistat Solid Dispersion
WO2015145324A1 (en)	2014-03-25	2015-10-01	Mylan Laboratories Ltd	Process for the preparation of cobicistat
US20160145344A1 (en) *	2014-10-20	2016-05-26	University Of Southern California	Murine and human innate lymphoid cells and lung inflammation
US10166185B2 (en) *	2015-06-09	2019-01-01	J. Rettenmaier & Söhne Gmbh + Co Kg	Excipient and oral solid dosage forms for oily drugs
WO2016201119A1 (en) *	2015-06-09	2016-12-15	J. Rettenmaier & Söhne Gmbh + Co Kg	Excipient and oral solid dosage forms for oily drugs
TW201728582A (zh) *	2016-01-28	2017-08-16	基利科學股份有限公司	結晶型
WO2018029565A1 (en)	2016-08-08	2018-02-15	Hetero Labs Limited	A multi-class anti-retroviral composition
US11045423B2 (en)	2016-08-08	2021-06-29	Hetero Labs Limited	Anti-retroviral compositions
EA202191370A1 (ru) *	2018-12-14	2021-09-16	Фуджифилм Корпорэйшн	Фармацевтическая композиция и способ ее получения
CN110251476B (zh) *	2019-08-01	2022-08-09	海思科制药(眉山)有限公司	一种恩曲他滨替诺福韦药物组合物
CN113425702B (zh) *	2021-06-25	2022-08-26	中国药科大学	应用微流控技术制备纳米颗粒、制备方法及装置和用途

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3400197A (en)	1965-01-26	1968-09-03	Robins Co Inc A H	Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules
GB1241024A (en)	1968-10-29	1971-07-28	Boehringer Sohn Ingelheim	Pharmaceutical tablet base and a process for its manufacture
FR2096292A5 (pt)	1970-06-15	1972-02-11	Sumitomo Chemical Co
CH586568A5 (pt)	1972-04-10	1977-04-15	Hoffmann La Roche
DE2845326C2 (de)	1978-10-18	1985-05-23	Beiersdorf Ag, 2000 Hamburg	Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung
US4603143A (en)	1983-05-02	1986-07-29	Basf Corporation	Free-flowing, high density, fat soluble vitamin powders with improved stability
GB8413191D0 (en)	1984-05-23	1984-06-27	Beecham Group Plc	Pharmaceutical composition
FR2609958B1 (fr)	1987-01-27	1995-03-10	Honda Motor Co Ltd	Dispositif de support pour roues arriere de motocyclettes
FR2631620B1 (fr)	1988-05-19	1990-07-27	Rhone Poulenc Chimie	Nouvelle silice precipitee absorbante et composition a base de cette s ilice
US5354866A (en)	1989-05-23	1994-10-11	Abbott Laboratories	Retroviral protease inhibiting compounds
US5552558A (en)	1989-05-23	1996-09-03	Abbott Laboratories	Retroviral protease inhibiting compounds
IE913840A1 (en)	1990-11-20	1992-05-20	Abbott Lab	Retroviral protease inhibiting compounds
GB9109862D0 (en)	1991-05-08	1991-07-03	Beecham Lab Sa	Pharmaceutical formulations
ZA923641B (en)	1991-05-21	1993-02-24	Iaf Biochem Int	Processes for the diastereoselective synthesis of nucleosides
ATE143262T1 (de)	1992-12-29	1996-10-15	Abbott Lab	Inhibitoren der retroviralen protease
GB9301192D0 (en)	1993-06-09	1993-06-09	Trott Francis W	Flower shaped mechanised table
WO1995005808A1 (en)	1993-08-24	1995-03-02	Abbott Laboratories	Oil-based tableting method
US5559158A (en) *	1993-10-01	1996-09-24	Abbott Laboratories	Pharmaceutical composition
US5585115A (en)	1995-01-09	1996-12-17	Edward H. Mendell Co., Inc.	Pharmaceutical excipient having improved compressability
US5948438A (en)	1995-01-09	1999-09-07	Edward Mendell Co., Inc.	Pharmaceutical formulations having improved disintegration and/or absorptivity
GB9514464D0 (en)	1995-07-14	1995-09-13	Glaxo Lab Sa	Medicaments
JP4064476B2 (ja)	1996-03-29	2008-03-19	エラワンファーマスーティカルリサーチアンドラボラトリーカンパニーリミテッド	二酸化珪素を有する球状凝集した澱粉
US6348216B1 (en)	1996-06-10	2002-02-19	Knoll Pharmaceutical Company	Ibuprofen and narcotic analgesic compositions
US6361794B1 (en)	1996-06-12	2002-03-26	Basf Corporation	Method of making ibuprofen and narcotic analgesic composition
US5922695A (en)	1996-07-26	1999-07-13	Gilead Sciences, Inc.	Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5939090A (en)	1996-12-03	1999-08-17	3M Innovative Properties Company	Gel formulations for topical drug delivery
JP4494539B2 (ja)	1997-02-28	2010-06-30	ディーエスエムアイピーアセッツビー．ブイ．	流動自由な乾燥粒子
FR2767071B1 (fr)	1997-08-06	1999-09-10	Rhodia Chimie Sa	Composition comprenant un liquide absorbe sur un support a base de silice precipitee
JP4027535B2 (ja)	1998-05-26	2007-12-26	エーザイ・アール・アンド・ディー・マネジメント株式会社	脂溶性薬物を含有した粉末
US6342249B1 (en)	1998-12-23	2002-01-29	Alza Corporation	Controlled release liquid active agent formulation dosage forms
CA2311734C (en)	2000-04-12	2011-03-08	Bristol-Myers Squibb Company	Flash-melt oral dosage formulation
US20020076437A1 (en)	2000-04-12	2002-06-20	Sanjeev Kothari	Flashmelt oral dosage formulation
US20030035834A1 (en)	2000-05-26	2003-02-20	Pawan Seth	Sustained release verapamil pharmaceutical composition free of food effect and a method for alleviating food effect in drug release
CN1247188C (zh)	2000-09-19	2006-03-29	第一制药株式会社	药物组合物
US7056951B2 (en)	2000-09-26	2006-06-06	Mutual Pharmaceutical Co., Inc.	Stable solid dosage forms of amino acids and processes for producing same
US6524615B2 (en)	2001-02-21	2003-02-25	Kos Pharmaceuticals, Incorporated	Controlled release pharmaceutical composition
DE10112651A1 (de)	2001-03-16	2002-09-19	Degussa	Inhomogene Kieselsäuren als Trägermaterial
YU81503A (sh)	2001-05-01	2006-08-17	Pfizer Products Inc.	Postupak za proizvodnju farmaceutskog preparata sa niskom dozom, koji ima uniformnu raspodelu i snagu leka
PL367221A1 (en) *	2001-05-18	2005-02-21	Lonza Ag	Method for the production of solid formulations of sodium 3-hydroxy-3-methylbutyrate
DE10126163A1 (de)	2001-05-30	2002-12-05	Degussa	Pharmazeutische Zubereitungen
EP1406594B1 (en)	2001-07-06	2019-06-05	Veloxis Pharmaceuticals A/S	Controlled agglomeration
GB0123400D0 (en)	2001-09-28	2001-11-21	Novartis Ag	Organic compounds
US7815936B2 (en)	2001-10-30	2010-10-19	Evonik Degussa Gmbh	Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
DE10153078A1 (de)	2001-10-30	2003-05-22	Degussa	Verwendung von Granulaten auf Basis von pyrogen hergestelltem Siliciumdioxid in pharmazeutischen Zusammensetzungen
US20030206978A1 (en)	2001-11-29	2003-11-06	Bob Sherwood	Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
WO2003047551A1 (en)	2001-11-29	2003-06-12	Penwest Pharmaceutical Company	Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
US6926906B2 (en)	2002-02-20	2005-08-09	M./S. Strides, Inc.	Orally administrable pharmaceutical formulation
PA8576201A1 (es)	2002-07-10	2004-05-26	Pfizer Prod Inc	Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
DE10250711A1 (de)	2002-10-31	2004-05-19	Degussa Ag	Pharmazeutische und kosmetische Zubereitungen
JP3567162B1 (ja)	2002-11-20	2004-09-22	日本たばこ産業株式会社	４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
AR042095A1 (es)	2002-11-20	2005-06-08	Japan Tobacco Inc	Compuesto 4-oxoquinolina y aplicacion del mismo como inhibidor de integrasa de vih
US7189416B2 (en)	2002-11-23	2007-03-13	Glykon Technologies Group, Llc	Method for stable and controlled delivery of (-)-hydroxycitric acid
PL378368A1 (pl)	2003-01-14	2006-04-03	Gilead Sciences, Inc.	Kompozycje i sposoby wykorzystywane w skojarzonej terapii przeciwwirusowej
EP1596835A1 (en)	2003-02-19	2005-11-23	H. Lundbeck A/S	Method for preparation of an agglomerate using melt agglomeration
WO2004073689A1 (en)	2003-02-19	2004-09-02	Lifecycle Pharma A/S	Use of a silica or silica derivative as a sorption material
FR2851918B1 (fr)	2003-03-06	2006-06-16		Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication
JP4018664B2 (ja)	2003-04-30	2007-12-05	第一三共株式会社	安定化固形製剤
DE10337198A1 (de)	2003-08-13	2005-03-17	Degussa Ag	Träger auf Basis von Granulaten, die aus pyrogen hergestelltem Siliciumdioxiden hergestellt sind
US8025899B2 (en) *	2003-08-28	2011-09-27	Abbott Laboratories	Solid pharmaceutical dosage form
JP2005075826A (ja)	2003-08-29	2005-03-24	Boehringer Ingelheim Internatl Gmbh	多孔質シリカ担体を含有する徐放性製剤
WO2005032525A1 (en)	2003-10-03	2005-04-14	Lifecycle Pharma A/S	A method for preparing modified release pharmaceutical compositions
US20070014846A1 (en)	2003-10-10	2007-01-18	Lifecycle Pharma A/S	Pharmaceutical compositions comprising fenofibrate and atorvastatin
KR20060085686A (ko)	2003-10-10	2006-07-27	라이프사이클 파마 에이/에스	피브레이트를 포함하는 고형 제제
US20050096390A1 (en)	2003-10-10	2005-05-05	Per Holm	Compositions comprising fenofibrate and pravastatin
US20050096391A1 (en)	2003-10-10	2005-05-05	Per Holm	Compositions comprising fenofibrate and rosuvastatin
US20060068015A1 (en)	2003-10-10	2006-03-30	Per Holm	Solid dosage form comprising a fibrate and a statin
US9173847B2 (en)	2003-10-10	2015-11-03	Veloxis Pharmaceuticals A/S	Tablet comprising a fibrate
US20050095287A1 (en)	2003-10-29	2005-05-05	Matharu Amol S.	Fosinopril composition
EP1729766A1 (en)	2004-03-01	2006-12-13	LEK Pharmaceuticals D.D.	Pharmaceutical formulation
MY142989A (en)	2004-03-10	2011-02-14	Bayer Schering Pharma Ag	Stabilised supersaturated solids of lipophilic drugs
WO2005105040A2 (en)	2004-04-26	2005-11-10	Micelle Products, Inc.	Water-soluble formulations of fat soluble vitamins and pharmaceutical agents and their applications
MY134672A (en)	2004-05-20	2007-12-31	Japan Tobacco Inc	Stable crystal of 4-oxoquinoline compound
AU2005256322C1 (en)	2004-06-28	2011-07-07	Veloxis Pharmaceuticals, Inc.	Porous tablets as carriers for liquid formulations
US20060009603A1 (en) *	2004-07-09	2006-01-12	David Young	Fibrillation-resistant polypropylene tape
AR045841A1 (es) *	2004-09-28	2005-11-16	Richmond Sa Com Ind Y Financie	Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r, 8r, 10r,11r)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla.
TWI375560B (en)	2005-06-13	2012-11-01	Gilead Sciences Inc	Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh)	2005-06-13	2015-02-01	Bristol Myers Squibb & Gilead Sciences Llc	單一式藥學劑量型
US20070014854A1 (en)	2005-07-15	2007-01-18	Ilan Zalit	Novel granulation process
JP2007039338A (ja)	2005-07-29	2007-02-15	Hirofumi Takeuchi	シリカ系複合顆粒
NZ569349A (en)	2005-12-14	2012-01-12	Cipla Ltd	Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit
WO2007074472A2 (en)	2005-12-27	2007-07-05	Jubilant Organosys Limited	Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxide
US20090186081A1 (en)	2006-01-05	2009-07-23	Lifecycle Pharma A/S	Disintegrating Loadable Tablets
US20100285157A1 (en)	2006-02-20	2010-11-11	Asahi Breweries, Ltd	Granules, tablets and method of producing the same
WO2007111866A2 (en)	2006-03-23	2007-10-04	Schering Corporation	Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto
SI2049506T2 (sl) *	2006-07-07	2024-07-31	Gilead Sciences, Inc.	Modulatorji farmakokinetičnih lastnosti terapevtikov
BRPI0714265A2 (pt) *	2006-08-10	2013-04-16	Cipla Ltd	composiÇço oral sàlida, processo para preparar uma composiÇço oral sàlida, uso de uma composiÇço e mÉtodo para tratar hiv
US20090281132A1 (en) *	2006-09-04	2009-11-12	Kiran Kumar Narsaiah Velaveni	Pharmaceutical formulation for use in hiv therapy
US7749537B2 (en)	2006-12-04	2010-07-06	Scolr Pharma, Inc.	Method of forming a tablet
PL2487161T5 (pl)	2007-02-23	2024-09-09	Gilead Sciences, Inc.	<div>Modulatory właściwości farmakokinetycznych środków terapeutycznych</div><div> </div>
CN101743004A (zh)	2007-06-29	2010-06-16	吉里德科学公司	治疗用组合物及其用途
BRPI0813000A2 (pt)	2007-06-29	2014-12-23	Gilead Sciences Inc	Composições terapêuticas e uso das mesmas
WO2009037449A1 (en)	2007-09-18	2009-03-26	Cipla Limited	Solid pharmaceutical compositions comprising one or more herpes virus inhibitors and one or more reverse transcriptase inhibitors
BRPI0911871A8 (pt)	2008-05-02	2018-03-06	Gilead Sciences Inc	uso de partículas veículo sólidas para melhorar a processabilidade de um agente farmacêutico
PL2393485T3 (pl)	2009-02-06	2015-12-31	Gilead Sciences Inc	Dwuwarstwowe tabletki zawierające elwitegrawir, kobicystat, emtrycytabinę i tenofowir
EP2238979A1 (en)	2009-04-06	2010-10-13	LEK Pharmaceuticals d.d.	Active pharmaceutical ingredient adsorbed on solid support
TW201728582A (zh)	2016-01-28	2017-08-16	基利科學股份有限公司	結晶型

2009
- 2009-05-01 BR BRPI0911871A patent/BRPI0911871A8/pt not_active IP Right Cessation
- 2009-05-01 EP EP15184628.4A patent/EP3006032A1/en not_active Withdrawn
- 2009-05-01 EA EA201591353A patent/EA201591353A1/ru unknown
- 2009-05-01 EA EA201071173A patent/EA022950B1/ru unknown
- 2009-05-01 MX MX2010011963A patent/MX2010011963A/es active IP Right Grant
- 2009-05-01 SI SI200931286T patent/SI2296633T1/sl unknown
- 2009-05-01 JP JP2011507697A patent/JP5722213B2/ja active Active
- 2009-05-01 SG SG2013033329A patent/SG190618A1/en unknown
- 2009-05-01 HU HUE09739981A patent/HUE026380T2/en unknown
- 2009-05-01 KR KR1020167025826A patent/KR101784647B1/ko active IP Right Grant
- 2009-05-01 KR KR1020107026980A patent/KR101659971B1/ko active IP Right Grant
- 2009-05-01 CA CA2720856A patent/CA2720856C/en active Active
- 2009-05-01 MX MX2014015438A patent/MX342377B/es unknown
- 2009-05-01 AP AP2010005429A patent/AP3089A/xx active
- 2009-05-01 CN CN201510408376.0A patent/CN104940937A/zh active Pending
- 2009-05-01 ES ES09739981.0T patent/ES2553897T3/es active Active
- 2009-05-01 NZ NZ588978A patent/NZ588978A/xx unknown
- 2009-05-01 SG SG10201609006WA patent/SG10201609006WA/en unknown
- 2009-05-01 CN CN200980115840XA patent/CN102123700A/zh active Pending
- 2009-05-01 PL PL09739981T patent/PL2296633T3/pl unknown
- 2009-05-01 AU AU2009242451A patent/AU2009242451C1/en active Active
- 2009-05-01 CN CN201310447258.1A patent/CN103479584A/zh active Pending
- 2009-05-01 US US12/434,513 patent/US10039718B2/en active Active
- 2009-05-01 PT PT97399810T patent/PT2296633E/pt unknown
- 2009-05-01 EP EP09739981.0A patent/EP2296633B1/en not_active Revoked
- 2009-05-01 WO PCT/US2009/042607 patent/WO2009135179A2/en active Application Filing
- 2009-05-01 DK DK09739981.0T patent/DK2296633T3/en active
2010
- 2010-10-11 IL IL208614A patent/IL208614A/en active IP Right Review Request
- 2010-10-28 CO CO10134187A patent/CO6321225A2/es not_active Application Discontinuation
- 2010-11-09 ZA ZA2010/08007A patent/ZA201008007B/en unknown
- 2010-11-26 EC EC2010010636A patent/ECSP10010636A/es unknown
2011
- 2011-08-02 HK HK11107966.2A patent/HK1153670A1/zh unknown
2013
- 2013-10-22 JP JP2013218876A patent/JP5925171B2/ja active Active
2014
- 2014-09-03 AU AU2014221210A patent/AU2014221210C1/en active Active
2015
- 2015-12-09 HR HRP20151357TT patent/HRP20151357T1/hr unknown
- 2015-12-22 CY CY20151101168T patent/CY1117067T1/el unknown
2016
- 2016-03-30 HK HK16103674.9A patent/HK1215679A1/zh unknown
- 2016-08-22 IL IL247417A patent/IL247417A0/en unknown
- 2016-10-28 AU AU2016250470A patent/AU2016250470A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PT2296633E (pt)	2015-12-04
CN103479584A (zh)	2014-01-01
CA2720856A1 (en)	2009-11-05
EP2296633A2 (en)	2011-03-23
EA201071173A1 (ru)	2011-08-30
WO2009135179A2 (en)	2009-11-05
MX342377B (es)	2016-09-27
HRP20151357T1 (hr)	2016-01-29
KR20110015581A (ko)	2011-02-16
WO2009135179A3 (en)	2011-05-19
HK1153670A1 (zh)	2012-04-05
IL208614A (en)	2016-09-29
AU2014221210B2 (en)	2016-08-18
CN102123700A (zh)	2011-07-13
SI2296633T1 (sl)	2015-11-30
AP3089A (en)	2015-01-31
SG190618A1 (en)	2013-06-28
DK2296633T3 (en)	2016-01-11
NZ588978A (en)	2013-01-25
EA201591353A1 (ru)	2016-01-29
SG10201609006WA (en)	2016-12-29
MX2010011963A (es)	2010-12-06
EP2296633B1 (en)	2015-09-30
AU2009242451C1 (en)	2017-05-18
EA022950B1 (ru)	2016-03-31
KR20160114728A (ko)	2016-10-05
CA2720856C (en)	2016-02-02
IL247417A0 (en)	2016-11-30
EP3006032A1 (en)	2016-04-13
ECSP10010636A (es)	2011-03-31
JP2011522790A (ja)	2011-08-04
KR101784647B1 (ko)	2017-10-11
JP2014012741A (ja)	2014-01-23
HK1215679A1 (zh)	2016-09-09
ES2553897T3 (es)	2015-12-14
KR101659971B1 (ko)	2016-09-26
US20090324729A1 (en)	2009-12-31
HUE026380T2 (en)	2016-06-28
AU2016250470A1 (en)	2016-11-17
CY1117067T1 (el)	2017-04-05
AP2010005429A0 (en)	2010-10-31
IL208614A0 (en)	2010-12-30
BRPI0911871A2 (pt)	2015-11-17
ZA201008007B (en)	2011-10-26
JP5925171B2 (ja)	2016-05-25
CN104940937A (zh)	2015-09-30
US10039718B2 (en)	2018-08-07
AU2014221210C1 (en)	2017-06-01
CO6321225A2 (es)	2011-09-20
JP5722213B2 (ja)	2015-05-20
PL2296633T3 (pl)	2016-03-31
AU2009242451A1 (en)	2009-11-05

Publication	Publication Date	Title
BRPI0911871A8 (pt)	2018-03-06	uso de partículas veículo sólidas para melhorar a processabilidade de um agente farmacêutico
BRPI1016219A2 (pt)	2016-04-26	composto, composição farmacêutica, e, uso de um composto
BRPI1008793A2 (pt)	2016-03-08	composto, uso de um composto, e, composição farmacêutica
BR112013008259A2 (pt)	2017-12-12	composto, composição farmacêutica, e, uso de um composto
BR112013015397A2 (pt)	2016-09-20	composto, composição farmacêutica, e, uso de um composto
AU2014221210A1 (en)	2014-09-25	The use of solid carrier particles to improve the processability of a pharmaceutical agent
BR112012002331A2 (pt)	2019-09-24	composição antiviral, composição farmacêutica e uso de quantidade efetiva de composição farmacêutica
BRPI0919942A2 (pt)	2014-12-23	Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt)	2017-05-23	composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt)	2015-12-29	composto, composição farmacêutica, e, uso de um composto
BR112014013760A2 (pt)	2017-06-13	composto, composição farmacêutica e uso de um composto
BR112013011448A2 (pt)	2016-08-09	composto, composição farnmacêutica, e, uso do composto
BRPI0917579A2 (pt)	2016-10-11	composto, composição farmacêutica, métodos, e, uso de um composto
BRPI0921879A2 (pt)	2018-10-16	composto, composição farmacêutica , e, uso de um composto
BR112012000652A2 (pt)	2016-02-10	composições contendo partículas de liberação de agente de benefício
BR112014005669A2 (pt)	2017-04-04	composto, composição farmacêutica e uso de um composto
BR112014003567A2 (pt)	2018-08-14	composto, uso de um composto, e, composição farmacêutica
BR112012031226A2 (pt)	2018-03-06	composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica
BRPI0906937A2 (pt)	2016-04-19	composto, composição farmacêutica, e, uso de um composto
BRPI0917026A2 (pt)	2016-02-16	uso de sucralose como agente granulador
BR112014013177A2 (pt)	2017-06-13	composto, composição farmacêutica e uso de um composto
BRPI1007186A2 (pt)	2016-02-23	composto, composição farmacêutica, e, uso de um composto
BRPI0919165A2 (pt)	2015-12-08	composição farmacêutica,e, uso de um composto
BRPI0915473A2 (pt)	2015-11-10	composto, composição farmacêutica, e, uso de um composto
BR112014013178A2 (pt)	2017-06-13	composto, composição farmacêutica e uso de um composto

Legal Events

Date	Code	Title	Description
2018-03-06	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2020-02-27	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 11A ANUIDADE.
2020-08-25	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2564 DE 2020-02-27